A systematic review of the effectiveness of adalimumab

110
Health economics
TABLE 66 Sensitivity analyses: TNF inhibitors in third place, early RA values
Scenario Adal – Base Etan – Base Adal+MTX – Etan+MTX – Infl+MTX –
Base Base Base
Base case 34,600 30,400 30,200 28,500 30,400
No HAQ progression on TNF inhibitors 21,200 18,700 19,100 17,800 19,500
Slow HAQ progression on all DMARDs 43,000 38,800 36,300 36,000 39,000
Slow HAQ progression on all treatments 54,600 45,600 43,200 42,000 45,300
Fast HAQ progression on all treatments 49,400 45,200 40,500 41,000 42,100
No effect of HAQ on mortality 32,200 29,200 28,400 27,400 29,200
Mortality ratio 2.73 per unit HAQ 36,100 31,400 31,000 29,400 31,200
Effectiveness of conventional DMARDs
down 50%
26,600 22,600 23,100 22,100 24,300
Effectiveness of conventional DMARDs
up 50%
49,600 43,400 40,200 39,000 41,300
Survival times on conventional DMARDs
down 50%
27,800 24,900 25,100 23,800 25,200
Survival times on conventional DMARDs
up 50%
39,200 34,400 34,300 33,400 34,300
Survival times on TNF inhibitors down 50% 36,700 32,000 32,200 29,600 33,400
Survival times on TNF inhibitors up 50% 33,200 29,800 28,200 27,700 28,800
Review at 12 weeks 33,700 30,400 29,700 28,500 30,300
Short-term quitters on TNF inhibitors
down 50%
35,300 30,800 30,700 29,000 31,300
Short-term quitters on TNF inhibitors
up 50%
33,800 30,500 29,200 28,300 30,200
Short-term quitters on conventional
DMARDs down 50%
34,100 30,800 29,900 28,300 30,900
Short-term quitters on conventional
DMARDs up 50%
32,500 29,100 28,600 27,300 28,900
Include offset costs 32,400 28,900 28,100 27,100 28,400